10.94
price up icon4.59%   0.48
after-market After Hours: 10.94
loading
Oruka Therapeutics Inc stock is traded at $10.94, with a volume of 225.34K. It is up +4.59% in the last 24 hours and up +0.27% over the past month. Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
See More
Previous Close:
$10.46
Open:
$10.23
24h Volume:
225.34K
Relative Volume:
0.75
Market Cap:
$409.60M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+10.39%
1M Performance:
+0.27%
6M Performance:
-61.04%
1Y Performance:
+0.00%
1-Day Range:
Value
$10.04
$11.03
1-Week Range:
Value
$9.58
$11.03
52-Week Range:
Value
$9.53
$31.13

Oruka Therapeutics Inc Stock (ORKA) Company Profile

Name
Name
Oruka Therapeutics Inc
Name
Phone
650-606-7910
Name
Address
855 OAK GROVE AVE., MENLO PARK
Name
Employee
28
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
ORKA's Discussions on Twitter

Compare ORKA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ORKA
Oruka Therapeutics Inc
10.94 409.60M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.01 128.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
744.83 81.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
571.00 34.69B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
233.07 30.17B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.66 26.02B 3.32B -860.46M -1.04B -8.32

Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-04-25 Initiated Wolfe Research Outperform
Oct-11-24 Initiated Stifel Buy
Oct-07-24 Initiated H.C. Wainwright Buy
Sep-17-24 Initiated Leerink Partners Outperform
Sep-16-24 Initiated TD Cowen Buy
Sep-13-24 Initiated Jefferies Buy
Feb-27-18 Initiated Ascendiant Capital Markets Buy
Oct-09-13 Initiated Dawson James Buy
View All

Oruka Therapeutics Inc Stock (ORKA) Latest News

pulisher
Mar 09, 2025

Oruka Therapeutics (NASDAQ:ORKA) Earns “Outperform” Rating from Wedbush - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

We're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn Rate - Yahoo Finance

Mar 08, 2025
pulisher
Mar 08, 2025

Oruka Therapeutics at Risk: Navigating Licensing Challenges and Partner Reliance - TipRanks

Mar 08, 2025
pulisher
Mar 07, 2025

Oruka Therapeutics Says ORKA-002 Preclinical Data Support Potential Extended Dosing Intervals - Marketscreener.com

Mar 07, 2025
pulisher
Mar 07, 2025

Oruka Therapeutics: Buy Rating Backed by Strong Financials and Promising Clinical Progress - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Oruka Therapeutics Announces Preclinical Data for ORKA-002 - GlobeNewswire

Mar 07, 2025
pulisher
Mar 07, 2025

Stifel maintains Buy rating on Oruka Therapeutics stock, $49 target - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting - The Manila Times

Mar 07, 2025
pulisher
Mar 06, 2025

Oruka Therapeutics Posts Q4 Net Loss -March 06, 2025 at 05:18 pm EST - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Oruka Therapeutics Reports 2024 Financial Results and Progress on Psoriasis Pipeline Including ORKA-001 and ORKA-002 - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

Can Oruka's $394M War Chest Transform Autoimmune Disease Treatment? Key Pipeline Updates - StockTitan

Mar 06, 2025
pulisher
Feb 28, 2025

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires $106,396.06 in Stock - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Insider Buying: Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires 88,794 Shares of Stock - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Oruka Therapeutics sees $1.41 million in stock purchases by Venrock - Investing.com Australia

Feb 28, 2025
pulisher
Feb 27, 2025

Oruka Therapeutics sees $1.41 million in stock purchases by Venrock Healthcare - Investing.com

Feb 27, 2025
pulisher
Feb 22, 2025

Oruka Therapeutics (ORKA) to Release Earnings on Thursday - Defense World

Feb 22, 2025
pulisher
Feb 20, 2025

Contrasting Virax Biolabs Group (NASDAQ:VRAX) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World

Feb 20, 2025
pulisher
Feb 19, 2025

Oruka Therapeutics to Present at Multiple March Investor Conferences - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

Can This Clinical-Stage Biotech's March Conference Circuit Signal Major Developments? - StockTitan

Feb 19, 2025
pulisher
Feb 17, 2025

Oruka Therapeutics (NASDAQ:ORKA) & Alpha Teknova (NASDAQ:TKNO) Head-To-Head Contrast - Defense World

Feb 17, 2025
pulisher
Feb 15, 2025

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Feb 15, 2025
pulisher
Feb 15, 2025

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Feb 15, 2025
pulisher
Feb 11, 2025

HC Wainwright Reaffirms Buy Rating for Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat

Feb 11, 2025
pulisher
Feb 10, 2025

Financial Fitness Check: Examining Oruka Therapeutics Inc (ORKA)’s Key Ratios - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Oruka Therapeutics Inc (ORKA) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle

Feb 10, 2025
pulisher
Feb 09, 2025

Oruka Therapeutics (NASDAQ:ORKA) Upgraded to Strong-Buy at Wolfe Research - MarketBeat

Feb 09, 2025
pulisher
Feb 08, 2025

After Falling -15.24% During The Past Week, Should You Still Buy Oruka Therapeutics Inc (NASDAQ: ORKA)? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Vor Biopharma Inc (NASDAQ: VOR) Stock Falling -15.06% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Oruka Therapeutics (NASDAQ:ORKA) Now Covered by Analysts at Wolfe Research - MarketBeat

Feb 08, 2025
pulisher
Feb 07, 2025

Oruka Therapeutics (NASDAQ:ORKA) Shares Gap UpTime to Buy? - MarketBeat

Feb 07, 2025
pulisher
Feb 07, 2025

Oruka Therapeutics inks exclusive license deal with Paragon - MSN

Feb 07, 2025
pulisher
Feb 06, 2025

Wolfe Research Begins Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World

Feb 06, 2025
pulisher
Feb 06, 2025

Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wolfe Research - Defense World

Feb 06, 2025
pulisher
Feb 05, 2025

Wolfe Research Initiates Coverage of Oruka Therapeutics (ORKA) with Outperform Recommendation - MSN

Feb 05, 2025
pulisher
Feb 04, 2025

This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Feb 04, 2025
pulisher
Feb 04, 2025

Oruka Therapeutics initiated with an Outperform at Wolfe Research - MSN

Feb 04, 2025
pulisher
Feb 02, 2025

Oruka Therapeutics (ORKA) Expected to Announce Earnings on Thursday - MarketBeat

Feb 02, 2025
pulisher
Jan 30, 2025

Oruka Therapeutics (ORKA) Projected to Post Earnings on Thursday - Defense World

Jan 30, 2025
pulisher
Jan 27, 2025

Abio Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Arca Biopharma, Inc. Is Fair to Shareholders - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 21, 2025

Brokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Target Price at $43.17 - MarketBeat

Jan 21, 2025
pulisher
Jan 21, 2025

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of “Buy” from Analysts - Defense World

Jan 21, 2025

Oruka Therapeutics Inc Stock (ORKA) Financials Data

There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$35.96
price up icon 0.98%
$21.98
price down icon 8.97%
$32.75
price down icon 0.79%
$317.87
price up icon 0.62%
$105.35
price down icon 3.15%
biotechnology ONC
$242.66
price down icon 1.78%
Cap:     |  Volume (24h):